Richard Scott Struthers is CEO & President at Crinetics Pharmaceuticals, Inc. (CRNX). They have made 8 open-market trades across 1 company since 2020, most recently 2026-08-07.
CIK 0001746298
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $65K since 2020, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CRNX | 424,706 | $36.1M |
Shares reported on the most recent Form 4, priced at the 2026-08-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CRNX | SELL · 10b5-1 | 2026-03-16 | 2026-03-18 | $37.37 | $822K | -4.0% | +14.8% | -1.8% |
| CRNX | SELL · 10b5-1 | 2025-09-26 | 2025-09-30 | $45.00 | $180K | +8.3% | +4.3% | +14.5% |
| CRNX | SELL · 10b5-1 | 2025-03-19 | 2025-03-21 | $34.19 | $1.2M | -9.3% | -12.9% | -12.9% |
| CRNX | SELL · 10b5-1 | 2024-12-02 | 2024-12-04 | $57.57 | $576K | -4.0% | -6.6% | -40.2% |
| CRNX | SELL · 10b5-1 | 2024-05-08 | 2024-05-10 | $49.40 | $10.6M | +4.9% | -6.5% | +5.4% |
| CRNX | SELL · 10b5-1 | 2024-04-04 | 2024-04-08 | $49.17 | $4.0M | -7.3% | +9.7% | -2.2% |
| CRNX | SELL | 2023-11-02 | 2023-11-06 | $30.56 | $12.2M | -6.2% | +10.0% | +24.7% |
| CRNX | SELL | 2023-07-11 | 2023-07-13 | $20.21 | $2.0M | -9.0% | -17.6% | +32.9% |
| CRNX | SELL | 2023-06-16 | 2023-06-21 | $20.81 | $2.1M | -8.1% | -4.6% | +49.8% |
| CRNX | SELL | 2022-04-13 | 2022-04-15 | $26.83 | $7.4M | -19.9% | -22.0% | -19.7% |
| CRNX | SELL | 2022-04-05 | 2022-04-07 | $25.34 | $1.1M | +1.8% | -27.7% | -9.8% |
| CRNX | SELL | 2021-09-07 | 2021-09-09 | $25.00 | $250K | -12.1% | -17.8% | +12.3% |
| CRNX | BUY | 2020-12-02 | 2020-12-04 | $13.00 | $65K | +5.1% | +5.3% | +9.1% |
| CRNX | SELL | 2020-07-15 | 2020-07-17 | $14.74 | $774K | +3.9% | +12.0% | +8.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.